Finally several studies are also exploring the role of PARP inhibitors in combination with radiotherapy in different tumor types, including NSCLC, head and neck cancer, esophageal cancer, and pancreatic cancer. This evidence concerns the gene PARP1 and non-small cell lung carcinoma.